BMS’s Zeposia (ozanimod) Receives the CHMP’s Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease
BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma
Shots:
- The approval is based on P-III SUNBEAM & RADIANCE Part B studies assessing Zeposia (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI) vs Avonex (qw, IM) in 1,346 & 1,320 patients with RMS for at least 12 & 24mos. treatment period respectively
- The results will further be reviewed by the European Commission, which has the authority to approve medicines for the European Union
- Zeposia (ozanimod) is an oral S1P receptor modulator involved in binding with S1P receptors 1 and 5. On Mar 25, 2020 the US FDA approved Zeposia for the treatment of adults with relapsing forms of multiple sclerosis (RMS)
Click here to read full press release/ article | Ref: BMS | Image: BMS